Severe, Symptomatic Hypocalcemia due to Denosumab Administration: Treatment and Clinical Course

Denosumab is a receptor activator of nuclear factor kappa-B (RANK) ligand inhibitor used in the treatment of osteoporosis. Blockade of RANK ligand prevents osteoclastic resorption of bone, but in doing so impairs the parathyroid hormone (PTH)-driven maintenance of serum calcium. A subsequent elevati...

Descripción completa

Detalles Bibliográficos
Autores principales: Strickling, Jarred, Wilkowski, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514500/
https://www.ncbi.nlm.nih.gov/pubmed/31192226
http://dx.doi.org/10.1159/000499824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514500/
https://www.ncbi.nlm.nih.gov/pubmed/31192226
http://dx.doi.org/10.1159/000499824

Ejemplares similares